Novel antibodies against follicular non-Hodgkin's lymphoma

被引：13

作者：

van Meerten, Tom ^{[2
]}

Hagenbeek, Anton ^{[1
]}

机构：

[1] Univ Amsterdam, Acad Med Ctr, Dept Hematol, NL-1105 AZ Amsterdam, Netherlands

[2] Univ Med Ctr Utrecht, Dept Hematol, Utrecht, Netherlands

来源：

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2011年 / 24卷 / 02期

关键词：

follicular Lymphoma; monoclonal antibody; CD20; B-CELL LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; ANTI-CD20; MONOCLONAL-ANTIBODY; PHASE-II TRIAL; ENDOTHELIAL GROWTH-FACTOR; FC-GAMMA-RIIIA; REGULATES SIGNAL-TRANSDUCTION; DIRECT ANTILYMPHOMA ACTIVITY; COMPLEMENT-MEDIATED LYSIS; FRESH-FROZEN PLASMA;

D O I：

10.1016/j.beha.2011.03.002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The anti-CD20 monoclonal antibody rituximab has revolutionized the treatment of patients with follicular B-cell lymphoma. With the combination of chemotherapy and rituximab the overall survival rate has increased with approximately 30%. Unfortunately, there is resistance to rituximab with relapse of the disease in about 60% of the patients during the first five years of treatment and eventually in all patients. To this end, there is a need to develop improved anti-CD20 monoclonal antibodies and antibodies that target other attractive molecules expressed on the follicular lymphoma cell. This review describes the development and clinical achievements so far of next generation anti-CD20 and other antibodies in the treatment of follicular B-cell lymphoma. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：231 / 256

页数：26

共 213 条

[1] Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study [J].

Advani, Anjali ;

Coiffier, Bertrand ;

Czuczman, Myron S. ;

Dreyling, Martin ;

Foran, James ;

Gine, Eva ;

Gisselbrecht, Christian ;

Ketterer, Nicolas ;

Nasta, Sunita ;

Rohatiner, Ama ;

Schmidt-Wolf, Ingo G. H. ;

Schuler, Martin ;

Sierra, Jorge ;

Smith, Mitchell R. ;

Verhoef, Gregor ;

Winter, Jane N. ;

Boni, Joseph ;

Vandendries, Erik ;

Shapiro, Mark ;

Fayad, Luis .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) :2085-2093

[2] Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma [J].

Advani, Ranjana ;

Forero-Torres, Andres ;

Furman, Richard R. ;

Rosenblatt, Joseph D. ;

Younes, Anas ;

Ren, Hong ;

Harrop, Kate ;

Whiting, Nancy ;

Drachman, Jonathan G. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) :4371-4377

[3] Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma [J].

Al-Katib, Ayad M. ;

Aboukameel, Amro ;

Mohammad, Ramzi ;

Bissery, Marie-Christine ;

Zuany-Amorim, Claudia .

CLINICAL CANCER RESEARCH, 2009, 15 (12) :4038-4045

[4] Epidemiology of the non-Hodgkin's lymphomas: Distributions of the major subtypes differ by geographic locations [J].

Anderson, JR ;

Armitage, JO ;

Weisenburger, DD .

ANNALS OF ONCOLOGY, 1998, 9 (07) :717-720

[5] Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma [J].

Ansell, Stephen M. ;

Horwitz, Steven M. ;

Engert, Andreas ;

Khan, Khuda Dad ;

Lin, Thomas ;

Strair, Roger ;

Keler, Tibor ;

Graziano, Robert ;

Blanset, Diann ;

Yellin, Michael ;

Fischkoff, Steven ;

Assad, Albert ;

Borchmann, Peter .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (19) :2764-2769

[6] Apoptosis control by death and decoy receptors [J].

Ashkenazi, A ;

Dixit, VM .

CURRENT OPINION IN CELL BIOLOGY, 1999, 11 (02) :255-260

[7] CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody [J].

Awan, Farrukh T. ;

Lapalombella, Rosa ;

Trotta, Rossana ;

Butchar, Jonathan P. ;

Yu, Bo ;

Benson, Don M., Jr. ;

Roda, Julie M. ;

Cheney, Carolyn ;

Mo, Xiaokui ;

Lehman, Amy ;

Jones, Jeffrey ;

Flynn, Joseph ;

Jarjoura, David ;

Desjarlais, John R. ;

Tridandapani, Susheela ;

Caligiuri, Michael A. ;

Muthusamy, Natarajan ;

Byrd, John C. .

BLOOD, 2010, 115 (06) :1204-1213

[8] Tumor regression in cancer patients by very low doses of a T cell-engaging antibody [J].

Bargou, Ralf ;

Leo, Eugen ;

Zugmaier, Gerhard ;

Klinger, Matthias ;

Goebeler, Mariele ;

Knop, Stefan ;

Noppeney, Richard ;

Viardot, Andreas ;

Hess, Georg ;

Schuler, Martin ;

Einsele, Hermann ;

Brandl, Christian ;

Wolf, Andreas ;

Kirchinger, Petra ;

Klappers, Petra ;

Schmidt, Margit ;

Riethmueller, Gert ;

Reinhardt, Carsten ;

Baeuerle, Patrick A. ;

Kufer, Peter .

SCIENCE, 2008, 321 (5891) :974-977

[9]

Barth MJ, 2010, J CLIN ONCOL S15, V28, P8095

[10] A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies [J].

Bartlett, Nancy L. ;

Younes, Anas ;

Carabasi, Matthew H. ;

Forero, Andres ;

Rosenblatt, Joseph D. ;

Leonard, John P. ;

Bernstein, Steven H. ;

Bociek, R. Gregory ;

Lorenz, Jennie M. ;

Hart, Bruce W. ;

Barton, Jeremy .

BLOOD, 2008, 111 (04) :1848-1854

← 1 2 3 4 5 6 7 8 9 10 →